Mineralys Insider Realizes $557K Options Gain Ahead of December FDA Date
David Malcom Rodman, Chief Medical Officer at Mineralys Therapeutics (NASDAQ:MLYS), executed a derivative options transaction that generated $557,000 in gains. The sale occurred under a pre-established Rule 10b5-1 trading plan and did not reflect immediate market conditions or insider knowledge of the December FDA event.
Tickers: $MLYS